cystetic Medicines, Inc., a clinical-stage biotechnology company developing small molecule channels that serve as molecular prosthetics for missing or dysfunctional CFTR protein channels, announced today that the first healthy volunteer has been dosed with CM001 in a Phase 1 clinical trial. CM001 is a molecular prosthetic intended to treat people with cystic fibrosis (CF).
cystetic Medicines Initiates Phase 1 Clinical Trial of a Molecular Prosthetic for Cystic Fibrosis wsiltv.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from wsiltv.com Daily Mail and Mail on Sunday newspapers.